Tags

Type your tag names separated by a space and hit enter

A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children.
Aliment Pharmacol Ther 2007; 25(2):177-84AP

Abstract

BACKGROUND

Functional abdominal pain disorders (FAPD) are common in school-aged children; however, there is no reliable treatment.

AIM

To determine the efficacy of Lactobacillus rhamnosus GG (LGG) for treating FAPD in children.

METHODS

A total of 104 children who fulfilled the Rome II criteria for functional dyspepsia (FD), or irritable bowel syndrome (IBS), or functional abdominal pain (FAP) were enrolled in a double-blind, randomized controlled trial in which they received LGG (n = 52), or placebo (n = 52) for 4 weeks.

RESULTS

For the overall study population, those in the LGG group were more likely to have treatment success (no pain) than those in the placebo group (25% vs. 9.6%, relative benefit (RB) 2.6, 95% confidence interval (CI): 1.05-6.6, number needed to treat (NNT) 7, 95% CI: 4-123). For children with IBS (n = 37), those in the LGG group were more likely to have treatment success than those in the placebo group (33% vs. 5%, RB 6.3, 95% CI: 1.2-38, NNT 4, 95% CI: 2-36) and reduced frequency of pain (P = 0.02), but not pain severity (P = 0.10). For the FD group (n = 20) and FAP group (n = 47), no differences were found.

CONCLUSION

The LGG appears to moderately increase treatment success, particularly among children with IBS.

Authors+Show Affiliations

Department of Paediatric Gastroenterology and Nutrition, The Medical University of Warsaw, Warsaw, Poland.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17229242

Citation

Gawrońska, A, et al. "A Randomized Double-blind Placebo-controlled Trial of Lactobacillus GG for Abdominal Pain Disorders in Children." Alimentary Pharmacology & Therapeutics, vol. 25, no. 2, 2007, pp. 177-84.
Gawrońska A, Dziechciarz P, Horvath A, et al. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25(2):177-84.
Gawrońska, A., Dziechciarz, P., Horvath, A., & Szajewska, H. (2007). A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Alimentary Pharmacology & Therapeutics, 25(2), pp. 177-84.
Gawrońska A, et al. A Randomized Double-blind Placebo-controlled Trial of Lactobacillus GG for Abdominal Pain Disorders in Children. Aliment Pharmacol Ther. 2007 Jan 15;25(2):177-84. PubMed PMID: 17229242.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. AU - Gawrońska,A, AU - Dziechciarz,P, AU - Horvath,A, AU - Szajewska,H, PY - 2007/1/19/pubmed PY - 2007/5/22/medline PY - 2007/1/19/entrez SP - 177 EP - 84 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 25 IS - 2 N2 - BACKGROUND: Functional abdominal pain disorders (FAPD) are common in school-aged children; however, there is no reliable treatment. AIM: To determine the efficacy of Lactobacillus rhamnosus GG (LGG) for treating FAPD in children. METHODS: A total of 104 children who fulfilled the Rome II criteria for functional dyspepsia (FD), or irritable bowel syndrome (IBS), or functional abdominal pain (FAP) were enrolled in a double-blind, randomized controlled trial in which they received LGG (n = 52), or placebo (n = 52) for 4 weeks. RESULTS: For the overall study population, those in the LGG group were more likely to have treatment success (no pain) than those in the placebo group (25% vs. 9.6%, relative benefit (RB) 2.6, 95% confidence interval (CI): 1.05-6.6, number needed to treat (NNT) 7, 95% CI: 4-123). For children with IBS (n = 37), those in the LGG group were more likely to have treatment success than those in the placebo group (33% vs. 5%, RB 6.3, 95% CI: 1.2-38, NNT 4, 95% CI: 2-36) and reduced frequency of pain (P = 0.02), but not pain severity (P = 0.10). For the FD group (n = 20) and FAP group (n = 47), no differences were found. CONCLUSION: The LGG appears to moderately increase treatment success, particularly among children with IBS. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/17229242/full_citation L2 - https://doi.org/10.1111/j.1365-2036.2006.03175.x DB - PRIME DP - Unbound Medicine ER -